{"id":"NCT01005680","sponsor":"Eli Lilly and Company","briefTitle":"A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer","officialTitle":"A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2009-11-02","resultsPosted":"2013-12-13","lastUpdate":"2013-12-13"},"enrollment":256,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Pemetrexed","otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar","LY188011"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]}],"arms":[{"label":"Pemetrexed plus Cisplatin","type":"EXPERIMENTAL"},{"label":"Gemcitabine plus Cisplatin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Randomization to date of death from any cause up to 35.8 months post-randomization","effectByArm":[{"arm":"Pemetrexed Plus Cisplatin (PC)","deltaMin":17.54,"sd":null},{"arm":"Gemcitabine Plus Cisplatin (GC)","deltaMin":15.51,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.822"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":14},"locations":{"siteCount":8,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":125},"commonTop":["Neutropenia","Nausea","Leukopenia","Vomiting","Decreased appetite"]}}